A recent study indicates that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end traditional lifestyle regimens.
Published data in a leading medical journal demonstrates that while overweight individuals can lose about a fifth of their body weight while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"People purchasing these treatments need to be informed of the risk of rapid weight regain when the treatment concludes," warns expert Dr. Susan Jebb.
Such speed of recovery suggests a return to original weight in about a year and a half.
Analyzing Treatments
The analysis, which reviewed dozens of trials involving thousands of patients, contrasted the effects of these new drugs with older methods.
Scientists emphasize that people who lose weight through dieting usually have a slower creep back—around 100 grams monthly—after stopping.
The Reason for the Fast Rebound
Experts believe the way of the injections explains the accelerated weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations far above than the body's typical production might result in the system to produce less of its own natural GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement means appetite is no longer kept in check, making binge eating much more probable."
A Chronic Disease?
Health authorities recommend the injections for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals say that, due to the significant potential of relapse, the treatment should be considered life-long.
This opinion is reinforced by drug manufacturers, who say that the results "emphasize the persistent nature of obesity," akin to managing conditions like high blood pressure.
Patient Accounts
Individuals who have come off the jabs describe a powerful resurgence of appetite.
"I experienced a switch that goes on and you become ravenous," recalled a patient.
The struggle is exacerbated if individuals have not established permanent lifestyle or habit modifications during treatment.
Significant Adoption
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is more common among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while these medications are potent agents for weight loss, they are not a permanent solution and long-term success hinges on combined behavioural changes.